VEGFR-1/Flt-1 inhibition increases angiogenesis and improves muscle function in a mouse model of Duchenne muscular dystrophy
Open Access
- 1 June 2021
- journal article
- research article
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 21, 369-381
Abstract
No abstract availableKeywords
Funding Information
- Shire
This publication has 60 references indexed in Scilit:
- Vascular-targeted therapies for Duchenne muscular dystrophySkeletal Muscle, 2013
- Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancerJournal of Clinical Investigation, 2013
- A Two-Compartment Model of VEGF Distribution in the MousePLOS ONE, 2011
- mdx Mice Manifest More Severe Muscle Dysfunction and Diaphragm Force Deficits than Do mdx MiceThe American Journal of Pathology, 2011
- Hypoxia down-regulates sFlt-1 (sVEGFR-1) expression in human microvascular endothelial cells by a mechanism involving mRNA alternative processingBiochemical Journal, 2011
- Effect of VEGF on the Regenerative Capacity of Muscle Stem Cells in Dystrophic Skeletal MuscleMolecular Therapy, 2009
- Sarcolemma-localized nNOS is required to maintain activity after mild exerciseNature, 2008
- Primary Role of Functional Ischemia, Quantitative Evidence for the Two-Hit Mechanism, and Phosphodiesterase-5 Inhibitor Therapy in Mouse Muscular DystrophyPLOS ONE, 2007
- Vascular Endothelial Growth Factor and AngiogenesisPharmacological Reviews, 2004
- Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor.Proceedings of the National Academy of Sciences, 1993